Report cover image

Global CGRP Targeting Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20279212

Description

Summary

According to APO Research, the global CGRP Targeting Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for CGRP Targeting Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for CGRP Targeting Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the CGRP Targeting Drugs market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for CGRP Targeting Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the CGRP Targeting Drugs market include Alder Therapeutics, AbbVie Inc., Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for CGRP Targeting Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of CGRP Targeting Drugs, also provides the value of main regions and countries. Of the upcoming market potential for CGRP Targeting Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CGRP Targeting Drugs revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global CGRP Targeting Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global CGRP Targeting Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

CGRP Targeting Drugs Segment by Company


Alder Therapeutics

AbbVie Inc.

Amgen Inc.

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Lilly Inc.

Lundbeck

Novartis International AG

Teva

CGRP Targeting Drugs Segment by Type


CGRP Receptor Antagonists

CGRP Monoclonal Antibodies

CGRP Targeting Drugs Segment by Application


Specialty Clinic

Hospital

Others

CGRP Targeting Drugs Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CGRP Targeting Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the CGRP Targeting Drugs key companies, revenue, market share, and recent developments.
3. To split the CGRP Targeting Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions CGRP Targeting Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CGRP Targeting Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze CGRP Targeting Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Targeting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGRP Targeting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Targeting Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGRP Targeting Drugs industry.
Chapter 3: Detailed analysis of CGRP Targeting Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of CGRP Targeting Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of CGRP Targeting Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global CGRP Targeting Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global CGRP Targeting Drugs Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 CGRP Targeting Drugs Market Dynamics
2.1 CGRP Targeting Drugs Industry Trends
2.2 CGRP Targeting Drugs Industry Drivers
2.3 CGRP Targeting Drugs Industry Opportunities and Challenges
2.4 CGRP Targeting Drugs Industry Restraints
3 CGRP Targeting Drugs Market by Company
3.1 Global CGRP Targeting Drugs Company Revenue Ranking in 2024
3.2 Global CGRP Targeting Drugs Revenue by Company (2020-2025)
3.3 Global CGRP Targeting Drugs Company Ranking (2023-2025)
3.4 Global CGRP Targeting Drugs Company Manufacturing Base and Headquarters
3.5 Global CGRP Targeting Drugs Company Product Type and Application
3.6 Global CGRP Targeting Drugs Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global CGRP Targeting Drugs Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 CGRP Targeting Drugs Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 CGRP Targeting Drugs Market by Type
4.1 CGRP Targeting Drugs Type Introduction
4.1.1 CGRP Receptor Antagonists
4.1.2 CGRP Monoclonal Antibodies
4.2 Global CGRP Targeting Drugs Sales Value by Type
4.2.1 Global CGRP Targeting Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global CGRP Targeting Drugs Sales Value by Type (2020-2031)
4.2.3 Global CGRP Targeting Drugs Sales Value Share by Type (2020-2031)
5 CGRP Targeting Drugs Market by Application
5.1 CGRP Targeting Drugs Application Introduction
5.1.1 Specialty Clinic
5.1.2 Hospital
5.1.3 Others
5.2 Global CGRP Targeting Drugs Sales Value by Application
5.2.1 Global CGRP Targeting Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global CGRP Targeting Drugs Sales Value by Application (2020-2031)
5.2.3 Global CGRP Targeting Drugs Sales Value Share by Application (2020-2031)
6 CGRP Targeting Drugs Regional Value Analysis
6.1 Global CGRP Targeting Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global CGRP Targeting Drugs Sales Value by Region (2020-2031)
6.2.1 Global CGRP Targeting Drugs Sales Value by Region: 2020-2025
6.2.2 Global CGRP Targeting Drugs Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America CGRP Targeting Drugs Sales Value (2020-2031)
6.3.2 North America CGRP Targeting Drugs Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe CGRP Targeting Drugs Sales Value (2020-2031)
6.4.2 Europe CGRP Targeting Drugs Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific CGRP Targeting Drugs Sales Value (2020-2031)
6.5.2 Asia-Pacific CGRP Targeting Drugs Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America CGRP Targeting Drugs Sales Value (2020-2031)
6.6.2 South America CGRP Targeting Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa CGRP Targeting Drugs Sales Value (2020-2031)
6.7.2 Middle East & Africa CGRP Targeting Drugs Sales Value Share by Country, 2024 VS 2031
7 CGRP Targeting Drugs Country-level Value Analysis
7.1 Global CGRP Targeting Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global CGRP Targeting Drugs Sales Value by Country (2020-2031)
7.2.1 Global CGRP Targeting Drugs Sales Value by Country (2020-2025)
7.2.2 Global CGRP Targeting Drugs Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.3.2 USA CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.3.3 USA CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.4.2 Canada CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.5.2 Mexico CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Germany CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.7.2 France CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.7.3 France CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.8.2 U.K. CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.9.2 Italy CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.10.2 Spain CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Russia CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.14.2 China CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 China CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Japan CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.16.2 South Korea CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.17.2 India CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 India CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.18.2 Australia CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Brazil CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Argentina CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Chile CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Colombia CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Peru CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Israel CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.27.2 UAE CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Turkey CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.29.2 Iran CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt CGRP Targeting Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Egypt CGRP Targeting Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt CGRP Targeting Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Alder Therapeutics
8.1.1 Alder Therapeutics Comapny Information
8.1.2 Alder Therapeutics Business Overview
8.1.3 Alder Therapeutics CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.1.4 Alder Therapeutics CGRP Targeting Drugs Product Portfolio
8.1.5 Alder Therapeutics Recent Developments
8.2 AbbVie Inc.
8.2.1 AbbVie Inc. Comapny Information
8.2.2 AbbVie Inc. Business Overview
8.2.3 AbbVie Inc. CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.2.4 AbbVie Inc. CGRP Targeting Drugs Product Portfolio
8.2.5 AbbVie Inc. Recent Developments
8.3 Amgen Inc.
8.3.1 Amgen Inc. Comapny Information
8.3.2 Amgen Inc. Business Overview
8.3.3 Amgen Inc. CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.3.4 Amgen Inc. CGRP Targeting Drugs Product Portfolio
8.3.5 Amgen Inc. Recent Developments
8.4 Daiichi Sankyo Co., Ltd.
8.4.1 Daiichi Sankyo Co., Ltd. Comapny Information
8.4.2 Daiichi Sankyo Co., Ltd. Business Overview
8.4.3 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.4.4 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio
8.4.5 Daiichi Sankyo Co., Ltd. Recent Developments
8.5 Pfizer Inc.
8.5.1 Pfizer Inc. Comapny Information
8.5.2 Pfizer Inc. Business Overview
8.5.3 Pfizer Inc. CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Inc. CGRP Targeting Drugs Product Portfolio
8.5.5 Pfizer Inc. Recent Developments
8.6 Lilly Inc.
8.6.1 Lilly Inc. Comapny Information
8.6.2 Lilly Inc. Business Overview
8.6.3 Lilly Inc. CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.6.4 Lilly Inc. CGRP Targeting Drugs Product Portfolio
8.6.5 Lilly Inc. Recent Developments
8.7 Lundbeck
8.7.1 Lundbeck Comapny Information
8.7.2 Lundbeck Business Overview
8.7.3 Lundbeck CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.7.4 Lundbeck CGRP Targeting Drugs Product Portfolio
8.7.5 Lundbeck Recent Developments
8.8 Novartis International AG
8.8.1 Novartis International AG Comapny Information
8.8.2 Novartis International AG Business Overview
8.8.3 Novartis International AG CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.8.4 Novartis International AG CGRP Targeting Drugs Product Portfolio
8.8.5 Novartis International AG Recent Developments
8.9 Teva
8.9.1 Teva Comapny Information
8.9.2 Teva Business Overview
8.9.3 Teva CGRP Targeting Drugs Revenue and Gross Margin (2020-2025)
8.9.4 Teva CGRP Targeting Drugs Product Portfolio
8.9.5 Teva Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.